GSK (GSK) Projected to Release Earnings on Tuesday

GSK (NYSE:GSK) is projected to release its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect the company to announce earnings of $1.27 per share and revenue of $11.0198 billion for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 9:00 AM ET.

GSK Stock Performance

NYSE GSK opened at $51.38 on Friday. The company has a fifty day moving average of $51.58 and a two-hundred day moving average of $53.39. The company has a market capitalization of $103.92 billion, a PE ratio of 13.35, a P/E/G ratio of 3.27 and a beta of 0.35. GSK has a 1 year low of $36.75 and a 1 year high of $61.69. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.79 and a quick ratio of 0.52.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, July 9th. Stockholders of record on Friday, May 15th were issued a $0.44 dividend. This represents a $1.76 annualized dividend and a dividend yield of 3.4%. The ex-dividend date of this dividend was Friday, May 15th. GSK’s payout ratio is presently 46.49%.

Key GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: The FDA approved Jideytro for previously treated ROS1-positive non-small cell lung cancer, marking GSK’s first lung cancer approval and a new catalyst for its oncology pipeline. Article
• Positive Sentiment: Analysts and market commentary highlighted Jideytro’s approval as potentially undervalued, suggesting investors may be underestimating the earnings contribution from GSK’s precision oncology assets. Article
• Positive Sentiment: GSK also received approval in Canada for a prefilled syringe presentation of Shingrix, which should support vaccine convenience and commercial execution. Article
• Neutral Sentiment: Citigroup reaffirmed its neutral rating on GSK, indicating the approval news is positive but not enough to change the bank’s stance yet. Article

Institutional Trading of GSK

Several hedge funds have recently modified their holdings of the business. Triumph Capital Management purchased a new stake in shares of GSK in the third quarter valued at approximately $40,000. SkyView Investment Advisors LLC purchased a new position in GSK in the fourth quarter worth $302,000. Gabelli Funds LLC lifted its holdings in GSK by 17.8% in the second quarter. Gabelli Funds LLC now owns 7,960 shares of the pharmaceutical company’s stock valued at $306,000 after acquiring an additional 1,200 shares during the period. IHT Wealth Management LLC lifted its holdings in GSK by 12.1% in the second quarter. IHT Wealth Management LLC now owns 14,736 shares of the pharmaceutical company’s stock valued at $566,000 after acquiring an additional 1,589 shares during the period. Finally, Brighton Jones LLC purchased a new stake in shares of GSK during the 4th quarter worth $528,000. 15.74% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on GSK shares. Weiss Ratings downgraded GSK from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 11th. HSBC upgraded GSK from a “reduce” rating to a “hold” rating in a research note on Monday, July 6th. Wall Street Zen raised GSK from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Citigroup reiterated a “neutral” rating on shares of GSK in a research report on Friday. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of GSK in a research note on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, GSK has a consensus rating of “Hold” and an average price target of $53.00.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.